These findings emphasize the pivotal role of CTLA-4 inhibitors in combination therapy, particularly for patients with advanced-stage HCC, and highlight the potential for integrating these agents into multifaceted treatment strategies to maximize antitumor immune responses. Here, CTLA4 is linked to hepatocellular carcinoma.